Supernus Pharmaceuticals (SUPN) Positive Phase 3 Excitement Dampened By Failure At 600mg - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $63.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
